• Olaparib (AZD2281): Unlocking Synthetic Lethality in Homo...

  2026-02-24

  Explore the role of Olaparib, a selective PARP-1/2 inhibitor, in advancing BRCA-deficient cancer research and DNA damage response assays. This article uniquely examines synthetic lethality, emerging biomarkers, and innovative radiosensitization strategies, providing new insights for translational and preclinical studies.

• Plerixafor (AMD3100) and the CXCL12/CXCR4 Axis: Mechanist...

  2026-02-24

  This thought-leadership article, authored from APExBIO’s scientific marketing leadership, delivers a comprehensive analysis of Plerixafor (AMD3100) as a benchmark CXCR4 chemokine receptor antagonist. Integrating the latest mechanistic insights, comparative innovations, and actionable strategy—anchored by recent peer-reviewed findings—this piece guides translational researchers to maximize experimental and clinical impact while highlighting the evolving competitive landscape and future directions for CXCR4 axis modulation.

• (S)-(+)-Dimethindene maleate: Selective M2 Antagonist for...

  2026-02-23

  (S)-(+)-Dimethindene maleate is a highly selective M2 muscarinic receptor antagonist and histamine H1 antagonist, supporting rigorous autonomic regulation research and cardiovascular physiology studies. This article details its verified receptor selectivity, stable physicochemical properties, and practical integration into translational research workflows.

• 3-Deazaadenosine (SKU B6121): Practical Solutions for Met...

  2026-02-23

  This article provides an evidence-based, scenario-driven exploration of 3-Deazaadenosine (SKU B6121), anchoring its value in reproducible methylation and antiviral workflows. Through real laboratory challenges and current literature, biomedical researchers and lab technicians will discover how this SAH hydrolase inhibitor from APExBIO delivers robust data and workflow reliability across epigenetic and infection models.

• 17-AAG (Tanespimycin): Optimizing HSP90 Inhibition in Can...

  2026-02-22

  17-AAG (Tanespimycin) delivers robust, reproducible HSP90 chaperone inhibition across diverse cancer models, driving both apoptosis induction and client protein degradation. This guide demystifies practical workflows, advanced applications, and troubleshooting strategies to maximize antitumor activity and experimental reliability.

• AZD2461: Redefining PARP-1 Inhibition with Next-Gen Preci...

  2026-02-21

  Explore how AZD2461, a novel PARP inhibitor, delivers advanced modulation of the DNA repair pathway and overcomes Pgp-mediated drug resistance in breast cancer models. This article uniquely examines integrated in vitro methodologies and translational strategies for extending cancer relapse-free survival.

• AZD0156: Selective ATM Kinase Inhibitor for Cancer Research

  2026-02-20

  AZD0156 stands out as a potent and highly selective ATM kinase inhibitor, enabling researchers to dissect DNA damage response mechanisms and optimize cancer therapy models. Its robust selectivity, oral bioavailability, and application versatility empower high-fidelity workflows and advanced synthetic lethality studies. APExBIO ensures reproducible quality, making AZD0156 an essential tool for translational cancer research.

• AZD0156: Next-Generation ATM Inhibitor Advancing DNA Dama...

  2026-02-20

  Explore the unique mechanism and advanced applications of AZD0156, a selective ATM kinase inhibitor for cancer research, in regulating DNA double-strand break repair and genomic stability. This in-depth analysis reveals novel insights and experimental strategies that set AZD0156 apart for translational and preclinical studies.

• 3-Deazaadenosine: Benchmark SAH Hydrolase Inhibitor for M...

  2026-02-19

  3-Deazaadenosine is a potent S-adenosylhomocysteine hydrolase inhibitor and a key tool in methylation and antiviral research. It enables precise suppression of SAM-dependent methyltransferase activity, supports epigenetic regulation studies, and demonstrates preclinical efficacy against Ebola virus. This article summarizes its mechanism, benchmarks, and integration parameters for reproducible experimental workflows.

• AZD2461: Novel PARP Inhibitor for Breast Cancer Research

  2026-02-19

  AZD2461 is a next-generation poly (ADP-ribose) polymerase inhibitor that potently targets PARP-1 in breast cancer models. This article reviews the atomic mechanisms, evidence, and experimental parameters for AZD2461, highlighting its role in overcoming Pgp-mediated resistance and extending relapse-free survival.

• 3-Deazaadenosine: Precision Tool for Epigenetic and Antiv...

  2026-02-18

  Explore the multifaceted role of 3-Deazaadenosine as a S-adenosylhomocysteine hydrolase inhibitor for methylation research and preclinical antiviral studies. This article uncovers mechanistic details and emerging therapeutic insights that set it apart from existing resources.

• Olaparib (AZD2281): Selective PARP Inhibitor for BRCA-Def...

  2026-02-18

  Olaparib (AZD2281) stands out as a potent, selective PARP-1/2 inhibitor tailored for BRCA-deficient cancer research, enabling robust DNA damage response and radiosensitization studies. This guide details optimized experimental workflows, advanced applications, and troubleshooting strategies to maximize reproducibility and translational impact using APExBIO's trusted compound.

• AZD2461: Novel PARP Inhibitor Transforming Breast Cancer ...

  2026-02-17

  AZD2461 stands out as a next-generation poly (ADP-ribose) polymerase inhibitor, engineered to overcome Pgp-mediated resistance and extend relapse-free survival in challenging breast cancer models. This guide delivers actionable workflows, advanced applications, and troubleshooting strategies to harness AZD2461’s unique mechanistic strengths for modulating the DNA repair pathway.

• AZD2461: Novel PARP Inhibitor for Breast Cancer Research ...

  2026-02-17

  AZD2461 is a potent, next-generation poly (ADP-ribose) polymerase inhibitor for breast cancer research, offering nanomolar PARP-1 inhibition and robust efficacy in Pgp-mediated drug resistance models. It induces DNA damage-associated G2 phase arrest and extends relapse-free survival in preclinical tumor studies.

• Optimizing DNA Damage Response Assays with Olaparib (AZD2...

  2026-02-16

  This article delivers an evidence-based, scenario-driven guide for integrating Olaparib (AZD2281, Ku-0059436) (SKU A4154) into DNA damage response, cytotoxicity, and radiosensitization studies. By addressing five common laboratory challenges, we demonstrate how this selective PARP-1/2 inhibitor enhances reproducibility, sensitivity, and workflow confidence in BRCA-deficient cancer research.

11293 records 1/753 page Next 12345 下5页 Last page